ETH Zürich
↗Zurich, Switzerland
ETH Zürich is a world-renowned public research university in Zurich, Switzerland, consistently ranked among the top technical and scientific institutions globally. Founded in 1855, it serves as a primary engine for innovation in the Swiss life sciences sector, particularly through its Institute of Pharmaceutical Sciences (IPW) and the Department of Biosystems Science and Engineering (D-BSSE).
While not a traditional pharmaceutical company, ETH Zürich operates as a massive incubator for the industry, generating a record-breaking number of biotech and pharma spin-offs annually. Its research spans the entire drug development value chain, from fundamental target discovery and synthetic biology to advanced clinical diagnostics and digital health technologies. The institution maintains deep strategic partnerships with global pharma giants like Roche and Novartis, facilitating the translation of academic breakthroughs into commercial therapeutics.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Academic Research & Spin-off Incubation
SIZE & FINANCIALS
Employees:10000+
Revenue:$2B-$5B
Founded:1855
Ownership:government
Status:operating
FUNDING
Stage:Not applicable
Total Raised:$2.3B
Investors:Swiss Federal Government, Swiss National Science Foundation (SNSF), Innosuisse, European Research Council (ERC), ETH Foundation
PIPELINE
Stage:Discovery
Lead Drug Stage:Phase 2
Modalities:Small molecule, mAb, RNA, Cell therapy, Gene therapy, Synthetic biology, AI-driven drug discovery
Active Trials:100
Trial Phases:Phase 1: 40 | Phase 2: 15 | Phase 3: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:ETH Domain (Swiss Federal Government)
Subsidiaries:ETH Singapore SEC Ltd, Wyss Zurich (Joint with UZH), ETH transfer (TTO)
Key Partnerships:Roche (Next-Gen Bioengineers partnership for cell/gene therapy), Novartis (Collaborative research in molecular biology), Amgen (Amgen Scholars Program), Nestlé (Future Food Initiative and clinical nutrition), Vifor International (Kidney disease therapeutics)
COMPETITION
Position:Leader
Competitors:EPFL (École Polytechnique Fédérale de Lausanne), MIT (Massachusetts Institute of Technology), Stanford University, University of Oxford, University of Zurich (UZH)
LEADERSHIP
Key Executives:
Joël Mesot - President
Annette Oxenius - Vice President for Research
Effy Vayena - Vice President for Knowledge Transfer
Scientific Founders:Robert Grass (Functional Materials), Wendelin Stark (Chemical Engineering), Sai Reddy (Systems Immunology), Jeffrey Bode (Synthetic Chemistry)
Board Members:Michael Hengartner (President of the ETH Board), Barbara Janom Steiner (Vice President of the ETH Board), Kristin Becker van Slooten, Stefan Spiegel
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with ETH Zürich. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.